Streetbeat News

Revenues

DRVN

Driven Brands Hldgs (NASDAQ:DRVN) has received mixed analyst ratings over the past quarter, with a shift towards a more bullish stance in the last 30 days. The average 12-month price target is $18.00, marking a 13.59% decline from the previous target. Analysts from firms including Canaccord Genuity, RBC Capital, Piper Sandler, JP Morgan, and Morgan Stanley have adjusted their ratings and price targets, reflecting various market conditions and company performance. Driven Brands, a North American automotive services company, shows a positive revenue trend but faces challenges in market capitalization, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 2:00 pm

EOG

EOG Resources (NYSE:EOG) received mixed analyst ratings over the past three months, with a total of 13 ratings. The sentiment has shifted slightly towards indifference in the last 30 days. The average 12-month price target is now $145.0, down from $151.17, indicating a 4.08% decrease. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. EOG Resources, a significant oil and gas producer, reported a -7.15% revenue growth decline as of December 31, 2023, but maintains a strong net margin of 32.97% and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 2:00 pm

COSM

Cosmos Health has received regulatory approval to sell its Sky Premium Life nutritional supplements in the UAE market and has secured initial purchase orders. This expansion into the UAE represents a significant step for Cosmos Health in increasing its global footprint and tapping into new revenue streams.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 1:28 pm

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) announced a new study published in The Journal of Clinical Microbiology showcasing the clinical benefits of the T2Resistance Panel. The study, conducted in Europe, demonstrated the panel's high accuracy, rapid detection times, and its impact on clinical interventions in sepsis cases. The T2Resistance Panel, which detects antibiotic resistance genes directly from blood, is seen as a precursor to the company's planned U.S. market launch, following its Breakthrough Device designation by the FDA.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 1:06 pm

SCLX

Scilex Holding Company (SCLX) has responded to Health Canada's questions regarding the product composition of ELYXYB, an FDA-approved oral solution for acute migraine treatment. ELYXYB is under review by Health Canada for approval, with a decision expected in approximately 12 months. The drug is noted for its fast action and potential for low gastrointestinal side effects compared to other NSAIDs. The Canadian migraine therapeutics market is estimated to reach $400 million by 2025.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 1:04 pm

RF

Regions Financial (NYSE:RF) has received diverse analyst ratings over the last three months, with 8 analysts offering evaluations ranging from bullish to bearish. The average 12-month price target is $22.25, marking an 18.41% increase from the previous target of $18.79. Analysts from firms like Citigroup, Morgan Stanley, and Barclays have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Despite a revenue decline of -7.23% as of December 31, 2023, Regions Financial boasts a strong market capitalization, exceptional net margin of 20.29%, and above-average ROE and ROA, indicating robust financial management and performance.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 1:00 pm

STLD

Steel Dynamics (NASDAQ:STLD) has been evaluated by 4 analysts over the last three months, showing a shift towards a more cautious stance with 3 indifferent ratings in the last 30 days compared to 1 bullish rating a month ago. The average 12-month price target for STLD has been raised to $129.75, marking an 8.12% increase from the previous target of $120.00. The company operates scrap-based steel minimills and has faced a -12.28% decline in revenue growth as of December 31, 2023, but maintains strong profitability indicators such as a net margin of 10.02%, ROE of 4.78%, and ROA of 2.84%.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 1:00 pm

RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) received mixed analyst ratings with an average 12-month price target of $92.75, marking a 20.14% increase from the previous target. The company's financial health shows strong revenue growth and efficient cost management but faces challenges in ROE and ROA. Its market capitalization is below industry benchmarks, indicating potential growth constraints.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 1:00 pm

NFE

New Fortress Energy Inc. (NFE) has sold two emergency power plants in San Juan and Palo Seco, Puerto Rico, to the Puerto Rico Electric Power Authority (PREPA) for $373 million. Additionally, NFE secured an 80 TBtu gas supply contract with PREPA, doubling its gas supply volumes to these plants. These moves are part of NFE's commitment to enhancing Puerto Rico's energy infrastructure and stability.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 12:38 pm

CEG

Constellation (NASDAQ:CEG) has issued the first corporate green bond in the U.S. for $900 million with a 30-year term to finance nuclear energy projects. This initiative underscores the role of nuclear energy in achieving sustainability goals and marks a significant step in green financing. The bond will fund investments in maintenance, expansion, and life extensions of nuclear power generation. Crédit Agricole CIB served as the Green Structuring agent for this offering, which aligns with the Green Bond Principles and Green Loan Principles.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 12:22 pm